WO2023287730A8 - Tricyclic compounds - Google Patents

Tricyclic compounds Download PDF

Info

Publication number
WO2023287730A8
WO2023287730A8 PCT/US2022/036733 US2022036733W WO2023287730A8 WO 2023287730 A8 WO2023287730 A8 WO 2023287730A8 US 2022036733 W US2022036733 W US 2022036733W WO 2023287730 A8 WO2023287730 A8 WO 2023287730A8
Authority
WO
WIPO (PCT)
Prior art keywords
tricyclic compounds
cancer
tricyclic
compounds
treating
Prior art date
Application number
PCT/US2022/036733
Other languages
French (fr)
Other versions
WO2023287730A1 (en
Inventor
Sobhana Babu Boga
Rakesh Kumar SIT
Christian Cho-Hua LEE
Igor Mochalkin
Kevin Duane BUNKER
Peter Qinhua HUANG
Mohammad Al-Amin
Original Assignee
Recurium Ip Holdings, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recurium Ip Holdings, Llc filed Critical Recurium Ip Holdings, Llc
Publication of WO2023287730A1 publication Critical patent/WO2023287730A1/en
Publication of WO2023287730A8 publication Critical patent/WO2023287730A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Disclosed herein are tricyclic compounds, together with pharmaceutical compositions and methods for treating a cancer wherein the cancer may be associated with a KRAS mutation.
PCT/US2022/036733 2021-07-13 2022-07-11 Tricyclic compounds WO2023287730A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163221362P 2021-07-13 2021-07-13
US63/221,362 2021-07-13

Publications (2)

Publication Number Publication Date
WO2023287730A1 WO2023287730A1 (en) 2023-01-19
WO2023287730A8 true WO2023287730A8 (en) 2023-02-23

Family

ID=84919619

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/036733 WO2023287730A1 (en) 2021-07-13 2022-07-11 Tricyclic compounds

Country Status (2)

Country Link
TW (1) TW202317570A (en)
WO (1) WO2023287730A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997042192A1 (en) * 1996-05-07 1997-11-13 Basf Aktiengesellschaft Imidazoquinazolines, agents containing them and their use to combat fungi and animal pests
SG11202109422WA (en) * 2019-03-01 2021-09-29 Revolution Medicines Inc Bicyclic heterocyclyl compounds and uses thereof
JP2023504113A (en) * 2019-11-29 2023-02-01 ルピン・リミテッド substituted tricyclic compound
CN113354651B (en) * 2020-07-30 2022-07-22 四川大学 Pyrazolo [1,5-a ] quinazoline derivative and application thereof in preparation of medicines
WO2022156792A1 (en) * 2021-01-25 2022-07-28 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heterocyclic compounds as sos1 inhibitors

Also Published As

Publication number Publication date
TW202317570A (en) 2023-05-01
WO2023287730A1 (en) 2023-01-19

Similar Documents

Publication Publication Date Title
WO2023287730A8 (en) Tricyclic compounds
EP4268898A3 (en) Kras g12c inhibitors for treating cancer
MY196582A (en) PD-1/PD-L1 Inhibitors
MX2020012731A (en) Kras g12c inhibitors and methods of using the same.
CR20220584A (en) Fused tricyclic kras inhibitors
WO2018049152A8 (en) Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
MX2019008701A (en) Combination therapy involving diaryl macrocyclic compounds.
EP3983445A4 (en) Compositions and methods for treating cancer
EP3938354A4 (en) Compositions and methods for treating cancer
MX2022003930A (en) Camptothecin peptide conjugates.
WO2022031847A3 (en) Compositions and methods for inhibiting plp1 expression
EP3968785A4 (en) Compositions and methods for treating cancer
EP3908601A4 (en) Methods and compositions for treating cancer
EP3847283A4 (en) Compounds, compositions and methods for treating or preventing her-driven cancers
EP3965896A4 (en) Compositions and methods for treating cancer
MX2022008099A (en) Treatment of cancer with cdk12/13 inhibitors.
AU2020320233A8 (en) Anti-HER2/anti-4-1BB bispecific antibody and use thereof
WO2019046243A3 (en) Uv-initiated reactions in polymeric materials
EP4003351A4 (en) Methods and compositions for treating cancer
WO2020146700A8 (en) Lipid nanoparticles
WO2020047144A3 (en) Ophthalmic formulations, process for preparing the same and method for administering the same
ZA202200905B (en) Anti-egfr/anti-4-1bb bispecific antibody and use thereof
EP3983014A4 (en) Compositions and methods for treating cancer
EP3930705A4 (en) Methods and compositions for treating cancer
EP3994269A4 (en) Pharmaceutical compositions, kits and methods for treating tumors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22842725

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE